Results of stage 2 evaluation showed that 100% of injecting people gave birth to immunity. The vaccine is effective on the British variant.
Today, the team will report the phase 2 clinical trial results of the Covid-19 Nanocovax vaccine.
Phase 2 started the trial on February 26 on 554 volunteers at the Military Medical Academy and the Medical Center of Ben Luc district, Long An, ending on April 8.
Initially, the team evaluated the vaccine as well as expected. All 3 dose levels are safe. 100% of injecting people are immunocompromised at different levels.
In particular, the antibody index to neutralize the virus (the ability to destroy the SARS-CoV-2 virus) after 2 weeks of injection 2 in the 25mcg dose group showed the highest results, with over 90%, 2 groups of doses of 50mcg and 75mcg for the result is not significantly lower.
The Phase 2 trial of Nanocovax vaccine showed very good results
In phase 2, the team continued to confirm that the Nanocovax vaccine was effective with the British variant. The South African variant has not been tested.
On April 27, the research team will report to the Ethics Council in the field of biomedical medicine of the Ministry of Health for the final conclusion, choosing the optimal dose before moving on to phase 3 trial, scheduled to begin from 5/5 to.
In phase 3, the Nanocovax vaccine will test on 10,000-15,000 people, including overseas such as India, Indonesia ... At the Military Medical Academy, there are currently nearly 800 volunteers registered for the phase 3 trial.
If it is favorable, the phase 3 trial will be completed by the end of September, then Vietnam can produce the first Covid-19 vaccine.
In the near future, WHO will have official guidance on vaccine testing on the principle of comparison with officially licensed vaccines.
This will create more favorable conditions for the phase 3 vaccine trial in Vietnam, especially when compared with the domestic injectable AstraZeneca vaccine.
Nanogen's Nanocovax vaccine is the first Covid-19 vaccine in Vietnam to carry out a clinical trial, starting on December 17, 2020.
In addition to Nanocovax, the Covivac vaccine of the Institute of Vaccines and Medical Biologicals (IVAC) is also in phase 1 clinical trial, expected to be completed on May 15.